EUROFINS BIOLOGIE MOLECULAIRE FRANCE : revenue, balance sheet and financial ratios

EUROFINS BIOLOGIE MOLECULAIRE FRANCE is a French company founded 8 years ago, specialized in the sector Analyses, essais et inspections techniques. Based in NANTES (44300), this company of category GE shows in 2024 a revenue of 6.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - EUROFINS BIOLOGIE MOLECULAIRE FRANCE (SIREN 833458730)
Indicator 2024 2023 2022 2020 2019 2018 2017
Revenue 6 929 329 € 6 489 424 € 6 803 617 € 6 626 070 € 5 415 939 € N/C N/C
Net income 157 558 € -89 633 € -102 450 € -54 085 € -12 365 € 76 822 € -1 300 €
EBITDA 275 025 € -176 281 € -274 481 € 53 805 € 383 700 € -1 287 181 € -1 300 €
Net margin 2.3% -1.4% -1.5% -0.8% -0.2% N/C N/C

Revenue and income statement

In 2024, EUROFINS BIOLOGIE MOLECULAIRE FRANCE achieves revenue of 6.9 M€. Over the period 2019-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +5.1%. Vs 2023: +7%. After deducting consumption (1.1 M€), gross margin stands at 5.8 M€, i.e. a rate of 84%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 275 k€, representing 4.0% of revenue. Positive scissor effect: EBITDA margin improves by +6.7 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 158 k€, i.e. 2.3% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

6 929 329 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

5 805 012 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

275 025 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

175 408 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

157 558 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

4.0%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 55%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 1.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.013%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

54.556%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

1.616%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.002

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

19.1%

Solvency indicators evolution
EUROFINS BIOLOGIE MOLECULAIRE FRANCE

Sector positioning

Debt ratio
0.01 2024
2022
2023
2024
Q1: 0.0
Med: 9.99
Q3: 48.5
Excellent

In 2024, the debt ratio of EUROFINS BIOLOGIE MOLECUL... (0.01) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
54.56% 2024
2022
2023
2024
Q1: 11.63%
Med: 34.78%
Q3: 58.76%
Good +9 pts over 3 years

In 2024, the financial autonomy of EUROFINS BIOLOGIE MOLECUL... (54.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 0.87 years
Good +25 pts over 3 years

In 2024, the repayment capacity of EUROFINS BIOLOGIE MOLECUL... (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 168.54. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2.2x. Financial charges are adequately covered by operations.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

168.537

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

2.191

Liquidity indicators evolution
EUROFINS BIOLOGIE MOLECULAIRE FRANCE

Sector positioning

Liquidity ratio
168.54 2024
2022
2023
2024
Q1: 133.14
Med: 205.95
Q3: 337.03
Average +11 pts over 3 years

In 2024, the liquidity ratio of EUROFINS BIOLOGIE MOLECUL... (168.54) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
2.19x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.02x
Q3: 2.48x
Good +47 pts over 3 years

In 2024, the interest coverage of EUROFINS BIOLOGIE MOLECUL... (2.2x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 48 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 41 days. The company must finance 7 days of gap between collections and payments. Inventory turnover is 23 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 83 days of revenue, i.e. 1.6 M€ to permanently finance.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

1 599 151 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

48 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

41 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

23 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

83 j

WCR and payment terms evolution
EUROFINS BIOLOGIE MOLECULAIRE FRANCE

Positioning of EUROFINS BIOLOGIE MOLECULAIRE FRANCE in its sector

Comparison with sector Analyses, essais et inspections techniques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (41 transactions). This range of 284 141€ to 2 313 696€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
284k€ 1384k€ 2313k€
1 384 593 € Range: 284 141€ - 2 313 696€
NAF 5 année 2024

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 41 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Analyses, essais et inspections techniques)

Compare EUROFINS BIOLOGIE MOLECULAIRE FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Analyses, essais et inspections techniques

Frequently asked questions about EUROFINS BIOLOGIE MOLECULAIRE FRANCE

What is the revenue of EUROFINS BIOLOGIE MOLECULAIRE FRANCE ?

The revenue of EUROFINS BIOLOGIE MOLECULAIRE FRANCE in 2024 is 6.9 M€.

Is EUROFINS BIOLOGIE MOLECULAIRE FRANCE profitable?

Yes, EUROFINS BIOLOGIE MOLECULAIRE FRANCE generated a net profit of 158 k€ in 2024.

Where is the headquarters of EUROFINS BIOLOGIE MOLECULAIRE FRANCE ?

The headquarters of EUROFINS BIOLOGIE MOLECULAIRE FRANCE is located in NANTES (44300), in the department Loire-Atlantique.

Where to find the tax return of EUROFINS BIOLOGIE MOLECULAIRE FRANCE ?

The tax return of EUROFINS BIOLOGIE MOLECULAIRE FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does EUROFINS BIOLOGIE MOLECULAIRE FRANCE operate?

EUROFINS BIOLOGIE MOLECULAIRE FRANCE operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.